
Min Cheol Chang¹
Donghwi Park²

¹Department of Rehabilitation Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea;
²Department of Physical Medicine and Rehabilitation, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea

Objective: Although several researches of animal and human subjects have yielded promising results regarding intradiscal injection of platelet-rich plasma (PRP) for the management of intervertebral disc (IVD) pathologies, small sample sizes and unstandardized graft preparation procedures hampered these research efforts. Therefore, we conducted a meta-analysis to evaluate the effectiveness of intradiscal PRP injection for the treatment of discogenic lower back pain.

Methods: The PubMed, SCOPUS, Embase, and Cochrane Library databases were systematically searched for relevant studies published from January 01, 1980 to December 14, 2020. The keywords used for the search were (platelet-rich plasma AND (intradiscal OR back pain OR lumbar spine OR discogenic)). Filters were used to select studies with human participants; all study designs were included.

Results: After the systematic review, three articles, including one randomized control trial and two prospective observational studies, were included in the final analysis. Analysis of changes in visual analogue scale (VAS) scores showed that VAS scores were significantly reduced two and six months after intradiscal PRP injection (two months: standardized mean difference [SMD] = −0.837, 95% CI = −1.158 to −0.516, P < 0.001; six months: SMD = −1.430, 95% CI = −2.209 to −0.652, P < 0.001), but not after one month (SMD = −0.661, 95% CI = −1.346 to 0.023, P = 0.058). Regarding changes in Oswestry Disability Index (ODI), ODI scores were significantly reduced after six months (SMD = −0.964, 95% CI = −1.885 to −0.043, P = 0.040).

Conclusion: Intradiscal PRP injections are effective in relieving pain and improving disabilities caused by discogenic lower back pain. However, the pain-reducing effect significantly manifests two or six months after the injections, but not after one month.

Keywords: platelet-rich plasma, discogenic lower back pain, degenerative disc disease, intervertebral disc, review

Introduction

Lower back pain is one of the most common causes of pain among the general population and can lead to varying disabilities and high socioeconomic burden.¹² Most cases of lower back pain are self-limited; however, nearly 20% of patients with lower back pain recur within six months of the initial development and some patients then experience chronic symptoms. Although several spine structures have been known as generators of the pain, intervertebral disc (IVD) pathologies are responsible for nearly 40% of chronic low back pain cases.³
The IVD is the biggest avascular structure in the both of the human.\textsuperscript{4} Its limited vasculature is comprised of the metaphyseal arteries branches near the outer annulus.\textsuperscript{4} Thus, IVD relies on nutrients by passive diffusion from the surrounding end plate vessels.\textsuperscript{5} Therefore, an IVD has been known to have a poor healing ability due to its limitation of vascular supply and nutrition access.\textsuperscript{5} In the natural healing process of annular tears in an IVD, granulated tissue may form and abnormal nerve fibers might grow in the nucleus pulposus and annulus fibrosus. These changes cause discogenic pain by inflammation. In addition, this repetitive damage and healing process can lead to degenerative disc disease. These degenerative changes in the IVD result in cellular and morphologic changes, causing collagen fibers loss, proteoglycans, fibrocartilage, and increased enzymatic activity.

Various treatment options including physical therapy,\textsuperscript{6} medication,\textsuperscript{7} injection of epidural steroids,\textsuperscript{8,9} and radiofrequency ablation,\textsuperscript{10} have been reported to manage the pain caused by IVD pathologies; however, these treatments cannot regenerate the structure of the disc. Moreover, a lot of patients have an insufficient response to these conservative treatments and their cases may even progress further to require surgical treatment such as lumbar fusion or disc replacement.\textsuperscript{11} However, these surgical treatment options have variable response rates and may cause serious complications.\textsuperscript{11}

In recent years, platelet-rich plasma (PRP) has been increasingly used for the treatment of patients with musculoskeletal pain. PRP is a mixture of fibrin and growth factor achieved from autologous peripheral blood.\textsuperscript{4} PRP is prepared by centrifuging autologous blood to obtain a concentrated platelet solution.\textsuperscript{4,12} Many previous studies of animal models and human subjects have demonstrated the efficacy of PRP for the treatment of diseases that require repair of damaged or degenerated collagen-based tissues, such as ligaments, cartilage, and tendons.\textsuperscript{13,14}

Given that an IVD is an avascular tissues with minimal regenerative ability, there has been increased interest in the use of PRP injections for the discogenic lower back pain management. The growth factors released by platelets include transforming growth factor (TGF) \(\beta-1\), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and epidermal growth factor (EGF); therefore, PRP injection in an IVD may result in cellular and tissue proliferation.\textsuperscript{15-18} Although researches of several animal\textsuperscript{19-22} and human subjects\textsuperscript{1,2,4} have yielded promising results regarding the use of intradiscal injection of PRP for the management of IVD pathologies, small sample sizes and unstandardized graft preparation procedures have hampered these research efforts. Therefore, to evaluate the effectiveness of intra-discal PRP injection for the management of discogenic lower back pain, we performed a meta-analysis of all available and relevant clinical studies of intradiscal PRP injection for the treatment of patients with discogenic lower back pain.

**Methods**

**Search Strategy**

This meta-analysis was conducted per the guidelines of Preferred Reporting Items for Systematic Review and Meta-Analysis. The PubMed, SCOPUS, Embase, and Cochrane Library databases were systematically searched for relevant studies published from January 01, 1980 to December 14, 2020. The keywords used for the search were (platelet-rich plasma) AND (intradiscal OR back pain OR lumbar spine OR discogenic). Select studies with human participants were selected by using filter. We included all design of the study; but, we only included articles published in English.

**Eligibility Criteria**

Articles were included in the present study based on the following criteria: 1) patients were treated for the alleviation of discogenic lower back pain; 2) intradiscal PRP injection was performed; and 3) visual analogue scale (VAS) or numeric rating scale (NRS) was used for evaluating the degree of pain. Review articles, case reports or letters, and studies that reported insufficient data/results were excluded from the meta-analysis.

**Study Selection and Data Extraction**

After the elimination of duplicate publications, two independent reviewers (MCC and DP) evaluated potential eligible studies to be included in the meta-analysis. Articles were screened for eligibility based on a review of their titles and abstracts; disagreements were resolved by consensus. After the primary screening, the two reviewers (MCC and DP) independently scrutinized the full texts of the eligible articles. Subsequently, data including the name of the first author, year of publication, sample size, demographic data, protocol for PRP injection, outcome measures [VAS and Oswestry Disability Index (ODI) scores], and major adverse events were independently extracted from each eligible article.
Quality Assessment
The methodological qualities of the studies included in the present meta-analysis were evaluated using two different tools. To determine adequate sequence generation, blinding, incomplete outcome data, allocation concealment, selective outcome reporting, and other potential sources of bias in the randomized control trials (RCTs), the Cochrane Collaboration’s Handbook were used. Judgments of bias were expressed as “low risk”, “high risk”, or “unclear risk.”23 Meanwhile, the Newcastle–Ottawa scale (NOS) was used to assess the quality of the prospective observational studies in three aspects of selection: selection of subjects, assessment of outcome, and comparability of groups.24 The quality of included study was graded as low (0–3), moderate (4–6), or high (7–9).24 By consensus, all divergences were resolved.

Statistical Analysis
Using the Comprehensive Meta-analysis Version 2 (Biostat Inc.), the extracted data were analyzed statistically. For each analysis, a heterogeneity test was conducted using the I² statistic, which can evaluate the inconsistency extent among results. If I² values were >50%, the data were considered to have substantial heterogeneity and the random-effects model was then used for data analysis. In contrast, if I² values were ≤50%, the pooled data were considered homogenous and the fixed effects model was applied for data analysis. Because the VAS and ODI scores are continuous variables, we evaluated the standardized mean differences (SMD) in changes from baseline and 95% confidence intervals (CI). Subgroup analyses were conducted per the evaluation time points. P < 0.05 was considered statistically significant. For studies in which pain was reported using the NRS, the values were converted into VAS score equivalents.

Results
Study Selection
A total of 1598 potentially relevant studies were selected in the preliminary search of all the databases (Figure 1). We excluded 133 duplicate studies and excluded an additional 1313 publications after their titles and abstracts were reviewed. The remaining studies were assessed through a review of the full texts of their articles. After the systematic review, three articles, which included one RCT and two prospective observational studies, were included in the final analysis (Table 1). The data of patients who received PRP injection in the RCT, which was conducted by Tuakli-Wosornu et al, were extracted.4

Study Characteristics
The selected researches included 71 cases. The follow-up duration after PRP injection ranged from two months to six months. The characteristics of the included researches are presented in Table 1.

Risk of Bias
The study by Tuakli-Wosornu et al4 was an RCT and the risk of bias was evaluated based on the domains of the Cochrane Handbook 5.1 Assessment Tool. The RCT had low risks of bias in allocation concealment, random sequence generation, blinding of participants and personnel, and blinding of the outcome assessment, selective reporting, incomplete outcome data, and in other domains. The two prospective observational studies1,2 were assessed using NOS; both studies were rated 8 stars, which indicates a low risk of bias (selection of subjects: three stars; comparability of groups: two stars; outcome assessment: three stars).

Meta-Analysis Results
Regarding the changes in VAS scores after PRP injection, we analyzed the data recorded one month, two months, and six months after the treatment; the I² values were 78.3%, 35.7%, and 65.5%, respectively. Therefore, the random-effects model was adopted for the analysis of the one-month and six-month outcomes (one month: P = 0.032, Tau² = 0.192, df = 1; six months: P = 0.089, Tau² = 0.208, df = 1), whereas the fixed-effects model was used to analyze the two-month outcomes (P = 0.212, Tau² = 0.032, df = 1).

Regarding ODI scores, the ODI scores recorded six months after the PRP injection were used; the I² values were 81.6%. Hence, for analyzing the six-month ODI data, the random-effects model was applied (P < 0.001, Tau² = 0.361, df = 1).

Analysis of the changes in VAS scores showed that the reduction of VAS scores after one month was not significant (SMD = −0.661, 95% CI = −1.346 to 0.023, P = 0.058) (Figure 2). However, VAS scores significantly reduced two and six months after intradiscal PRP injection (two months: SMD = −0.837, 95% CI = −1.158 to −0.516, P < 0.001; six months: SMD = −1.430, 95% CI = −2.209 to −0.652, P < 0.001).
Analysis of the changes in ODI scores revealed that ODI scores were significantly reduced six months after intradiscal PRP injection (SMD = -0.964, 95% CI = -1.885 to -0.043, P = 0.040) (Figure 3).

No adverse events were reported in all three included studies.

**Publication Bias**
In each analysis, the data of two studies were used. Therefore, funnel plot analyses and quantification of the publication bias were not conducted.

**Discussion**
In the present study, we evaluated the effectiveness of intradiscal PRP injections for the treatment of patients with discogenic lower back pain. To the best of our knowledge, this study is the first meta-analysis to analyze the effect of intradiscal PRP injection on pain reduction in patients with discogenic lower back pain.

We evaluated all data in each included study and the results showed that lower back pain and disability caused by lower back pain were significantly improved two months and six months after intradiscal PRP injections,
but not one month after. The effect size (SMD) of VAS reduction after two months of intradiscal PRP injections was −0.837 and that after six months of intradiscal PRP injections was −1.430. The effect size (SMD) of ODI reduction at six months after PRP injections was −0.964. Based on Cohen’s d statistic, these effect sizes indicate that intradiscal PRP injections have large positive pain-reducing and functional improving effects in patients with discogenic lower back pain.

There are some proposed possible mechanisms behind the pain reducing and disc healing effect of intradiscal PRP injection. It has been reported that the platelet concentration of PRP is three to eight times of that found in whole blood.\(^3\)\(^-\)\(^5\);\(^\)\(^6\)\(^-\)\(^8\)\(^,\) it has also been reported that PRP contains higher levels of cytokines and growth factors, which can stimulate the process of tissue repair and healing.\(^3\)\(^-\)\(^5\);\(^\)\(^6\)\(^-\)\(^8\)\(^,\) Platelets secrete growth factors, such as insulin-like growth factor, EGF, TGF-β, PDGF, VEGF, and basic fibroblast growth factor, which are needed for tissue healing and repair.\(^5\)\(^-\)\(^8\) These growth factors and cytokines may promote angiogenesis, accelerate endothelial regeneration, and increase collagen content in different types of tissues.\(^5\)\(^-\)\(^8\) In addition, they may stimulate quiescent stem cells to further promote the tissue healing and repair process.\(^27\)

Theoretically, the regeneration and tissue healing process induced by intradiscal PRP injection may be more difficult than expected as the IVD is a complex and avascular structure relatively. However, in previous in vitro studies of human and animal disc cells, PRP demonstrated positive effects and growth factors released by PRP appeared to reduce apoptosis.\(^19\)\(^-\)\(^21\) Moreover, disc cells cultured with PRP exhibited improved annulus cell proliferation and proteoglycan synthesis. PRP has been reported to inhibit the inflammatory effect of interleukin-1 and TNF-α on cells of the nucleus pulposus.\(^28\) PRP also showed a beneficial effect on the experimentally injured discs of animals in vivo studies.\(^20\)\(^-\)\(^22\) The results of these trials show the protective effect of PRP on degenerated IVDs of study subjects compared to those of controls; the effects include restoration of disc height and T2 signals on spine magnetic resonance images.\(^22\) Notably, there were no safety issues in these trials, nor were there any mutations of the nucleus pulposus cells that indicate an increased cancer risk. Due to its invasive nature, intradiscal PRP injection can theoretically cause adverse events such as disk neurologic injury, space infection, or progressive herniation; however, there was no report of any adverse event after intradiscal PRP injection the three studies\(^1,2,4,23\) included in the present meta-analysis. However, to thoroughly investigate the safety of intradiscal PRP injection, future studies with follow-up durations longer than six months are necessary.

In this study, we could not perform the analysis with data extracted from placebo or control group patients. Of the three included studies, only Tuakli-Wosornu et al\(^4\) performed a study with a control group. The other two studies\(^1,2\) did not recruit placebo or control subjects. The recruitment of a placebo group is complicated with ethical issues because of the invasive nature of intradiscal injections. In addition,
Clinicians have limited options to control the discogenic lower back pain conservatively other than pain medications and physical therapy. Therefore, it would be difficult to find an appropriate procedure for the control group. However, despite these difficulties, the lack of placebo or control group is one of the limitations of the previous studies.

**Conclusion**

This study showed that intradiscal PRP injections are effective in relieving pain and improving disabilities caused by discogenic lower back pain. Notably, this pain-reducing effect significant manifests at two or six months after intradiscal PRP injections, but not one month after the injection. However, the present meta-analysis is limited in that we could not analyze data extracted from control or placebo groups. Of the three included studies included in this meta-analysis, only the RCT by Tuakli-Wosornu et al. included a control group. The authors compared the effect of intradiscal PRP injection with that of a control injection treatment (contrast agent). Placebo or control subjects were not recruited in the other two studies. Also, for the evaluation of the effectiveness of intradiscal PRP, only two measurements (VAS and ODI) were used.
Abbreviations
PRP, platelet-rich plasma; IVD, intervertebral disc; DDD, degenerative disc disease; VAS, visual analogue scale; VEGF, vascular endothelial growth factor; EGF, epidermal growth factor; TGF, transforming growth factor; PDGF, platelet-derived growth factor; ODIP, Newcastle–Ottawa scale; ODI, Oswestry Disability Index; RCT, randomized control trial; NRS, numeric rating scale; bFGF, basic fibroblast growth factor.

Ethical Publication Statement
We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Funding
The present study was supported by a National Research Foundation of Korea grant funded by the Korean government (grant no. NRF-2019M3E5D1A02068106).

Disclosure
The authors report no conflicts of interest in this work.

References